A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 16, 2022

Primary Completion Date

June 9, 2023

Study Completion Date

March 14, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

Abrocitinib 100 mg

Orally administered, abrocitinib 100 mg tablets QD

DRUG

Abrocitinib 200 mg

Orally administered, abrocitinib 200 mg tablets QD.

Trial Locations (15)

110026

Maharaja Agrasen Hospital, New Delhi

110029

All India Institute of Medical Sciences, New Delhi

110060

Sir Ganga Ram Hospital, New Delhi

160012

Postgraduate Institute of Medical Education & Research, Chandigarh

302017

Apex Hospitals Pvt. Ltd., Jaipur

334001

S. P. Medical College & A. G. Hospitals, Bikaner

390001

Government Medical College & Shri Sayajirao General Hospital, Vadodara

395002

Nirmal Hospital Pvt Ltd., Surat

411001

Jehangir Clinical Development Centre Pvt. Ltd., Pune

422101

Assured Care Plus Hospital, Nashik

431003

Mahatma Gandhi Mission's Medical College & Hospital, Aurangabad

440015

Orange City Hospital and Research Institute, Nagpur

560074

RajaRajeswari Medical College and Hospital, Bengaluru

575002

Father Muller Medical College Hospital, Mangalore

700073

Calcutta School of Tropical Medicine, Kolkata

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY